Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. We reported the final OS analysis from the original study population and within subgroups. B...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2020-02, Vol.12 (2), p.151-159
Main Authors: Bersanelli, Melissa, Buti, Sebastiano, Banna, Giuseppe Luigi, Giorgi, Ugo De, Cortellini, Alessio, Rebuzzi, Sara Elena, Tiseo, Marcello, Fornarini, Giuseppe, Mazzoni, Francesca, Panni, Stefano, Tursi, Michele De, Marino, Pietro Di, Rossetti, Sabrina, Rossi, Ernesto, Tomao, Silverio, Luca, Emmanuele De, Sorarù, Mariella, Mucciarini, Claudia, Atzori, Francesco, Torre, Leonardo La, Vitale, Maria Giuseppa, Martelli, Valentino, Sepe, Pierangela, Mollica, Veronica, Vaccaro, Vanja, Schinzari, Giovanni, Ficorella, Corrado, Massari, Francesco, Maestri, Antonio, Sabbatini, Roberto, Sava, Teodoro, Maio, Massimo Di, Verzoni, Elena, Procopio, Giuseppe, Giannarelli, Diana
Format: Article
Language:English
Subjects:
Cancer therapies
Cancer vaccines
Disease control
Dyspnea
flu vaccine
immune checkpoint inhibitors
Immunotherapy
Influenza
influenza syndrome
influenza vaccination
Lung cancer
Multivariate analysis
overall survival
Population
Population studies
Response rates
Survival
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. We reported the final OS analysis from the original study population and within subgroups. Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32–0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2019-0180